Q&A

Kidney Disease Progression: How to Attenuate Risk

Author and Disclosure Information

 

References

Despite the strengths of this study, it is worth noting that it did not consider stage of kidney disease, nor did it distinguish comorbidities of the patients. The retrospective chart review format did not allow for identification of concurrent medication use (including OTC and herbal products).

The National Institute of Diabetes and Digestive and Kidney Diseases is currently conducting an RCT to investigate the renoprotective effects of allopurinol versus placebo in diabetic patients. (Clinical Trials.gov identifier: NCT02017171). Enrollment was completed in 2014, and results are expected in June 2019.

One important proviso about allopurinol: While it is inexpensive and generally well tolerated, prescribers should be aware of rare sensitivity reactions, particularly Stevens-Johnson syndrome. —MRS

Mary Rogers Sorey, MSN
Division of Nephrology and Hypertension at Vanderbilt University Medical Center, Nashville

Pages

Recommended Reading

FDA Strengthens Kidney Warnings on Two Diabetes Drugs
Clinician Reviews
Nutrition Guidelines for CKD
Clinician Reviews
Expanding Treatment Options
Clinician Reviews
Newer Insulin Glargine Formula Curbs Nocturnal Hypoglycemia
Clinician Reviews
Data-based Recommendations for CKD Screening
Clinician Reviews
Data-based Recommendations for Dialysis
Clinician Reviews
CABG best for diabetes patients with CKD – or is it?
Clinician Reviews
Do Kidney Patients Know an App From a Nap?
Clinician Reviews
Kidney Disease & “Bad Teeth”
Clinician Reviews
Kidney Disease Progression: How to Calculate Risk
Clinician Reviews

Related Articles